Sulindac Sulfide Differentially Induces Apoptosis in Smac-Proficient and -Deficient Human Colon Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) like sulindac show potential in colon cancer prevention.
• Sulindac sulfide, the active metabolite, induces apoptosis through death receptor and mitochondrial pathways.
• Cross-talk between these apoptotic pathways is known, but the role of Second mitochondrial-derived activator (Smac) is unclear.

Purpose of the Study:

• To investigate the role of Smac in sulindac sulfide-induced apoptosis in human colon cancer cells.
• To elucidate the molecular mechanisms by which Smac influences sulindac sulfide's anti-cancer effects.

Main Methods:

• Utilized Smac-proficient and Smac-deficient human colon cancer cell lines.
• Analyzed sulindac sulfide-induced apoptosis markers, including death receptor 5 (DR5) upregulation and caspase activation (caspases 3, 9, and 8).
• Assessed cytochrome c release from mitochondria.

Main Results:

• Smac deficiency affected sulindac sulfide-induced apoptosis in colon cancer cells.
• Sulindac sulfide upregulated DR5 and activated caspases 3, 9, and 8 in Smac-proficient cells.
• Smac deficiency altered caspase activation and abrogated cytochrome c release, indicating Smac's involvement in mitochondrial pathway signaling.

Conclusions:

• Smac plays a significant role in sulindac sulfide-induced apoptotic signal transduction in human colon cancer cells.
• A potential cross-talk exists between Smac and cytochrome c release in this process.
• These findings contribute to understanding the molecular mechanisms of sulindac's chemopreventive effects.